MedPath

Effect of risperidone in breath-holding

Phase 2
Completed
Conditions
breath-holding.
Other abnormalities of breathing
R06.89
Registration Number
IRCT20200203046350N1
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
30
Inclusion Criteria

having experienced one or more breath-holding attack

Exclusion Criteria

Patients with a history of seizure

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of breath-holding attack. Timepoint: Before treatment to three months after treatment. Method of measurement: Number of breath-holding attacks based on observation.;Breath holding grade. Timepoint: Before treatment to three months after treatment. Method of measurement: breath-holding grade based on observation.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath